Browsing Tag
Incyte Corporation
8 posts
Ipsen to buy Kartos Therapeutics for up to $1.75bn as IPN nears 52-week high
Ipsen is buying Kartos for up to $1.75 billion. Read how navtemadlin could reshape its oncology pipeline, earnings outlook and IPN valuation after the deal.
Incyte stock in focus as $2bn Star Therapeutics deal nears for blood disorder pipeline
Incyte may buy Star Therapeutics for up to $2B. See why the deal matters for Jakafi risk and hematology growth.
Lilly bets up to $2.3bn on Ajax Therapeutics to crack the resistant myelofibrosis market with a Type II JAK2 inhibitor
Lilly is paying up to $2.3B for Ajax Therapeutics' Type II JAK2 inhibitor. The real question is whether it can crack Incyte's Jakafi grip on myelofibrosis.
Incyte (NASDAQ: INCY) moves closer to an hidradenitis suppurativa launch as 54-week povorcitinib data hold up
Incyte Corporation’s new 54-week povorcitinib data could reshape hidradenitis suppurativa treatment. Read what it means for INCY now.
Incyte breaks new ground in EU cancer care with first PD‑1 drug for tough gastrointestinal tumors
Discover how Incyte’s EU backing for its MacroGenics‑partnered cancer drug Zynyz could shift immunotherapy competition in gastrointestinal cancers.
Incyte’s Opzelura delivers Phase 3b win in moderate adult atopic dermatitis patients
Incyte’s Opzelura cream shows strong Phase 3b results in adults with moderate atopic dermatitis. Find out what this could mean for EU filings and future growth.
Could Eli Lilly and Incyte’s Olumiant redefine how adolescent alopecia areata is treated in 2025?
Find out how Eli Lilly and Incyte's Olumiant helped teens regrow hair in a new trial—could this redefine alopecia areata treatment for adolescents?
Incyte’s dual-target antibody and KRAS G12D drug show early promise in hard-to-treat colorectal and pancreatic cancers
Find out how Incyte’s Phase 1 cancer data could transform treatment for colorectal and pancreatic patients—read what’s driving investor optimism today!